Visit Biological Dynamics at Booth 10071.
Attend the 2024 ASCO Annual Meeting and be part of the most significant gathering of oncology professionals worldwide, making connections and forging collaborations that can change the landscape of cancer care.
Visit Biological Dynamics at Booth 4340.
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world
US HUPO 2024 features a full program of outstanding plenary speakers, a great variety of 14 parallel scientific sessions and oral presentations, as well as educational short courses and topic-specific evening workshops. Our oral presentation sessions cover diverse and fascinating proteomic topics, such as Enabling Pandemic Proteomics, Automation and Large-Scale Proteomics, Microbiome Multi-omics and Proteomics to Advance Equity.
Leveraging next gen technologies beyond conventional biomarker drug discovery!
MarketsandMarkets bring to you the 9th Annual Biomarker and CDx Conference - West Coast Edition scheduled to be held on 8th - 9th February 2024 in San Diego, USA. This event will have an introduction to turning biomarkers into companion diagnostics.
The Precision Medicine World Conference (PMWC) is an independent and established conference series considered to be the preeminent precision medicine conference that attracts recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration.
The 42nd Annual Healthcare Conference will take place on January 8-11, 2024 in San Francisco, CA.
This premier conference is the largest and most informative health care investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
Bringing together researchers and industry participants from both academia and industry, this established event will discuss the latest innovations and developments in EV/Exosomes fields from a Technology Development and Utilization Perspective.
There is an Extensive International Perspective at this Conference with Speakers, Poster Presenters, Sponsors, and Exhibitors from the US, Europe, and Asia/Pacific. Running alongside the conference will be an exhibition covering the latest technological advances and associated products and services from leading solution providers within this expanding field from around the world.
Visit us at Booth #E7.
Join us as Dr. Stuart Ibsen, Assistant Professor of Biomedical Engineering, School of Medicine at Oregon Health and Science University, and Rob Turner, VP of Product Development at Biological Dynamics discuss unlocking insights from extracellular vesicles!
Title: Unlocking Insights from Extracellular Vesicles: A Novel Approach to Pancreatic Cancer Detection
Date: Tuesday, November 14, 2023
Time: 1:00 PM Eastern Standard Time
Watch the replay of the webinar here!
AMP is the leading organization in the field of molecular diagnostics, and the AMP Annual meeting is the premier gathering of molecular professionals. As technologies change and new challenges arise, members and non-members alike rely on the AMP meeting to obtain the critical information needed to ensure that their patients receive the best care and best results.
Join us at our Corporate Workshop on November 15, 2023 at 8-8:50am in Room 251 BC. Rob Turner, M.Eng., Vice President, Product Development, Biological Dynamics will share the latest about the ExoVerita™ Pro technology.
Title: New Frontiers in Diagnostics: Simplifying High Purity Exosome Isolation with the ExoVerita™ Pro
Description: Extracellular vesicles, including exosomes, are cell-to-cell communication tools representing active tissues. Thus, exosomes offer the opportunity to intercept messages related to disease status. We will discuss how our automated platform, ExoVerita™ Pro, rapidly isolates highly purified exosomes from clinical samples, thereby enabling downstream analysis. The workshop will include discussion on recent results using ExoVerita Pro for early-stage cancer detection and how the system can be leveraged to empower other diagnostic applications. Attendees will have the opportunity to see and discuss the system with the developers and ask questions about how it can be used in their research.
Visit us at Booth #929.
ACG is a recognized leader in educating GI professionals and the general public about digestive disorders, and the Annual Scientific Meeting and Postgraduate Course is considered the premier GI clinical event of the year. It offers GI physicians the opportunity to network with peers, share experiences from their practice, learn the latest clinical information on key GI topics, and see the latest advances in gastrointestinal technology and therapeutics.
Visit us at Booth #1232.
Cancer Research UK, Canary Center at Stanford, and OHSU Knight Cancer Institute present the Early Detection of Cancer Conference series. The annual conference brings together experts in early detection from multiple disciplines to share groundbreaking research and progress in the field.
The Conference is part of a long-term commitment to invest in early detection research, to understand the biology behind early-stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.
Harmeet Dhani, MD, MSc, Medical Director, Biological Dynamics, presented a lightning talk on “Proteomic Expression Using Exosomes in Intraductal Papillary Mucinous Neoplasms (IPMN) Patients to Inform Risk Stratification," as part of the “Understanding Pre-cancers to Enable Early Detection” track.
The lightning talk demonstrates the ability of the ExoVita Pancreas assay to risk-stratify Intraductal Papillary Mucinous Neoplasms (IPMNs), the most common type of pancreatic cyst, in order to help inform treatment decisions for patients at risk of pancreatic cancer.
Unlock the power of exosomes with ExoVerita Pro!
As part of the University of Pennsylvania's EV Seminar Series, our VP of Product Development, Rob Turner, will guide you through the world of exosomes! He will demonstrate how our ExoVerita Pro platform is simplifying the isolation of exosomes into hours vs. days through an automated process.
This fascinating webinar is a must-see for researchers, scientists, and anyone interested in the latest advancements in exosome technology and early disease detection!
In a recent episode of the BioBreakthroughs podcast, host Jared S. Taylor sat down with Paul Billings, CEO of Biological Dynamics, to talk about the revolutionary advances our company is making in the field of liquid biopsies. With a strong foundation in medicine and biotechnology, Paul Billings shared how the focus on exosomes is transforming the early detection of pancreatic cancer and much more.
To watch the podcast, visit #15 - Paul Billings, CEO and Director of Biological Dynamics (sliceofhealthcare.com)
On August 15 at 10am PT, join us for an insightful webinar that delves into pancreatitis research and therapies: "New Pancreatitis Therapies: Current Clinical Trials," hosted by Mission: Cure.
The panel of experts, including Harmeet Dhani, M.D., M.Sc, Medical Director at Biological Dynamics, will educate and empower attendees by providing the latest information about currently recruiting clinical trials and the enrollment process.
Let's come together to learn, engage, and shape the future of pancreatitis research and treatment.
Watch the webinar replay: New Pancreatitis Therapies: Current Clinical Trials
The 2023 ASCO Annual Meeting is your all-access pass to join global cancer experts and discover the latest innovations in cancer research and education. This year's program will feature over 200 sessions complementing Dr. Eric Winer's Presidential theme Partnering With Patients: The Cornerstone of Cancer Care and Research.
Poster session on June 5, 2023 from 8AM to 11AM titled: "ExoLuminate: An observational registry study for detection of pancreatic adenocarcinoma (PDAC) in high-risk or clinically suspicious patients."
Visit us at Booth #24175.
The ISEV Annual Meeting is the premier scientific conference in the field of extracellular vesicles. They bring together the top researchers and scientists from around the world, showcasing cutting edge research in session rooms and cutting-edge technology on the exhibits floor. The ISEV Annual Meeting has grown to over 1,200 attendees annually.
The Biological Dynamics team joined pancreatic cancer survivors, their families, caregivers, supporters, and fellow researchers at the Pancreatic Cancer Action Network annual Purple Stride walk on April 29th! Together, we will make a great impact on pancreatic cancer awareness, early testing, and treatment.
The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.
Biological Dynamics will be presenting three posters this year, highlighting our work in early cancer detection for lung and pancreatic cancers. Stop by booth #1368 to learn more about our ExoVerita Platform and exosome enrichment services to support your research.
The 41st Annual Healthcare Conference will take place on January 9-12, 2023 in San Francisco, CA.
This premier conference is the largest and most informative healthcare investment symposium in the industry which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
Dr. Paul Billings, CEO and Kevin Han, CFO are scheduled to participate in a fireside chat with UBS analysts on Wednesday, August 10th at 1:00 p.m. ET / 10:00 a.m. PT. Webcast link
This three-day event will once again bring together key industry executives, institutional investors and UBS professionals from across the Genomics and MedTech sectors. Our carefully-curated agenda will include exclusive keynote speakers and thematic panel discussions in addition to presentations from a select group of high-quality, Genomics and MedTech Innovations companies. In addition, investors will have the opportunity to dialogue directly with corporates and management teams through one-on-one and small
CLINICAL LAB EXPO HALL
Visit AACC 2022 DISRUPTIVE TECHNOLOGY AWARD SEMIFINALIST Biological Dynamics at the Clinical Lab Expo Hall to learn more about our unique technology for early cancer detection. The 2022 AACC Annual Scientific Meeting & Clinical Lab Expo showcases the latest science and technology shaping the future of laboratory medicine. The annual event features vital research and important changes in the field, with more than 250 educational opportunities in the form of lectures, plenary, scientific, and roundtable sessions. SEE DETAILS >>
From Plenaries featuring world-renowned scientists to cutting-edge Scientific Sessions and intimate Roundtables geared for lively discussion on hot topics, the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo offers something for everyone in laboratory medicine.
AACC’s scientific program is designed to provide you with the knowledge you need to advance professionally, the skills to improve your practice, and opportunities to collaborate and learn from experts. Discover the meeting’s more than 250 educational opportunities in a variety of formats spanning the breadth of laboratory medicine. Use the Online Session Search to view the full conference program and find sessions by topic, speaker, or other features.
LIQUID BIOPSY SHOWCASE
PRESENTATION: Thursday, June 30, 2022
2:45 PM PT/5:45 PM ET
SESSION: Liquid Biopsy Showcase
JP Hinestrosa, Ph.D., Sr. Director, Research, Biological Dynamics will discuss the company’s disruptive technology designed to advance early cancer detection by leveraging its proprietary Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.
PRESENTATION ABSTRACT
Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.
The Liquid Biopsy Showcase features selected liquid biopsy companies that are advancing the development of tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).
PMWC, the “Precision Medicine World Conference” is the largest annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration in an effort to accelerate the development and spread of precision medicine.
Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology in clinical implementation (e.g., cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors
POSTER PRESENTATION: Friday, May 27, 2022
3:15 PM – 4:15 PM CET
SESSION ROOM: Forum 5 & 6
TITLE: PF01 – Technologies and methods: EV separation from blood
David Searson, Senior Process Engineer, Biological Dynamics to present the company’s latest data for early cancer detection.
PRESENTATION ABSTRACT:
Electrokinetic Isolation of Extracellular Vesicles from Pancreatic, Ovarian and Bladder Cancers Enables Early Detection
Extracellular vesicles (EVs) carry cancer biomarkers and are central to emerging liquid biopsy technologies; however, current EV isolation methods balance purity against efficiency. We investigated an alternating current electrokinetic (ACE) method to isolate EVs directly from plasma. We compared the ACE method against differential ultracentrifugation (DU) to study yield, purity and utility. EVs isolated by ACE were then used for detection of early-stage pancreatic, ovarian, and bladder cancers.
The annual ISEV meeting offers an unparalleled opportunity to learn from, teach, and network with, leading and emerging experts in EV research. The scope and quality of the scientific exchange makes ISEV2022 the world’s largest and the premier meeting in EV research. This event features the best in vesicle science, covering all aspects of fundamental, translational, and clinical research, disseminating cutting-edge developments in EV research. ISEV2022 brings together scientists from academic, clinics, and industry, who have a common goal of understanding EVs and applying this knowledge for societal and economic benefit.
PRESENTATION: Monday, May 16, 2022
7:00 AM. – 9:00 AM CST
PODIUM PD53-07, Room 255/Abstract ID: 22-7466
TITLE: Bladder Cancer – Basic Research & Pathophysiology III
Jean M. Lewis, Ph.D., Associate Director, Research, Biological Dynamics to present the company’s latest bladder cancer data.
PRESENTATION ABSTRACT
Detection of Early-stage Bladder Cancer Using Plasma Extracellular Vesicle Protein Biomarkers
There is a need for earlier bladder cancer screening to reduce lifetime costs and improve patient outcomes. Urinary protein biomarkers have shown some promise, but reported sensitivities appear compromised by low and/or variable biomarker concentrations. In this study, we investigated the potential of using extracellular vesicles (EV) circulating in the blood to detect stage I and II bladder cancer. Using an alternating current electrokinetic (ACE) platform to purify EVs from plasma, we show how a multi-marker EV protein-based methodology can be used to discriminate bladder cancer cases from controls in stage I and II cases.
AUA continues to be a leader in developing innovative, evidence-based quality education for urologists and urologic health care professionals worldwide. Through the Annual Meeting—and other year-round educational offerings—the AUA sets the highest standards for urologic education.
The Annual Meeting, in its 117th year, is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines, and the latest advances in urologic medicine. Attendees repeatedly report that the knowledge they take from the meeting positively impacts their practices.
LIVE PRESENTATION
Sunday, April 10, 2022, 4:20 – 4:35 PM (ET)
SESSION CATEGORY: New Targets and Strategies for Prevention and Risk Reduction
SESSION TITLE: 727 – Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins
PRESENTER: Juan P. Hinestrosa, PhD
VIRTUAL POSTER PRESENTATIONS:
Friday, April 8, 2022, 12:00 PM – 1:00 PM (ET)
SESSION CATEGORY: Preclinical Prevention, Early Detection, and Interception
SESSION TITLE: 5960 – Blood-based extracellular vesicle biomarker test for detection of early-stage pancreatic cancer
PRESENTER: Juan P. Hinestrosa, PhD
Friday, April 8, 2022, 12:00 PM – 1:00 PM (ET)
SESSION CATEGORY: Chemistry
SESSION TITLE: Proteomics and Mass Spectrometry
PERMANENT ABSTRACT NUMBER: 5082 – Proteomic analysis of extracellular vesicles from oncology donor samples purified using an alternating current electrokinetic microelectrode chip
PRESENTER: Jean M. Lewis, PhD
NOTE: Virtual posters are available online only and will not be presented live. Attendees can send questions to the presenter through the e-poster site or through the Networking feature of the virtual meeting platform. E-posters will be released at 12:00 PM CT on Friday, April 8, and will be available to registered attendees through Wednesday, July 13, 2022.
EVENT: Monday, April 4, 8:00 AM – Tuesday, April 5, 2022, 3:30 PM (ET)
PRESENTATION: Tuesday, April 5, 2022, 9:55 A.M. (ET)
Fireside Chat with Biological Dynamics
Dr. Paul Billings will discuss the interplay between therapeutic and diagnostic development; how molecular diagnostics impact therapeutic development; and using diagnostics to support revisiting data, global development, and global regulatory strategy.
Session Title: What Therapeutic Developers Should Look for in a Diagnostic Partner
CONFERENCE: Tuesday, March 22, 2022, 8:00 AM – Wednesday, March 23, 5:00 PM
OPENING KEYNOTE PANEL: Tuesday, March 22, 2022
9:00 – 9:45 AM
Interpreting the Current Reimbursement Climate for Diagnostic Testing Products
Dr. Paul Billings, Biological Dynamics, to participate in an interactive panel to discuss:
• Lessons learned: A look at strategies used throughout the pandemic
• Considerations impacting coverage for COVID products post-EUA
• Decoding reimbursement coverage trends for new technologies
• Assessing the current landscape regarding VALID & VITAL Acts
VIRTUAL EVENT
Participation: Tuesday, March 8, 2022
Biological Dynamics’ Kevin Han to participate in emerging product discussions on Tuesday, March 8, 2022. More than 375 public and private companies across the entire healthcare spectrum attend the invitation-only event.
The conference program includes high-interest panels covering a range of topics: key medical devices; life science and diagnostic tools; health care delivery; and the evolving political and regulatory landscape, all featuring renowned medical, scientific, industry, legal, and political consultants. Cowen analysts will answer investor questions submitted to the panel, and provide data-rich content to drive deeper discussion and insights, such as a comparison of clinical expert and payor views.
EVENT: Tuesday, March 1, 2022, 08:00 Central European Time (CET) – Wednesday, March 2, 2022, 18:00 (CET)
PRESENTATION: Wednesday, March 2
11:00 AM CET/5:00 AM EST
Dr. Jean M. Lewis, Associate Director of Research at Biological Dynamics, Inc., will discuss her team’s work developing exosome-based liquid biopsy assays using the company’s proprietary platform. The presentation, Multi-Cancer Early Detection Based on a Classifier for Extracellular Vesicle Biomarkers, illustrates the potential utility of EV-protein biomarkers in the non-invasive diagnosis of cancer applications. Recently, her research has been directed towards identifying EV biomarkers for early-stage cancer liquid biopsy.
Presentation Abstract
Simultaneous detection of multiple, early-stage cancers was tested using extracellular vesicle (EV) bound protein markers from plasma purified by an alternating current electrokinetic (ACE) microarray. In a case-control study, this method detected 95.7% of pancreatic, 75.0% of ovarian, and 43.8% of bladder cancers at 99.5% specificity, all at stages I and II. The initial results suggest that this liquid biopsy screen may have great promise for early-stage, multi-cancer screening.
Session Title: Technology Developments in the Circulating Biomarkers Space
SelectBio Circulating Biomarkers Europe brings together academics and industry participants from around the world focused on research, biomarker analyses and therapeutics development leveraging the cargo from Exosomes and Extracellular Vesicles (EVs). An important component of this conference is to focus upon the development of Liquid Biopsies using circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs) and other biomarkers found in biofluids.
Additionally, the conference focuses on the Therapeutic and Drug Delivery Opportunities Enabled by Extracellular Vesicles (EVs). In this vein, key opinion leaders in this space will be presenting at this conference.
Presentations, Panel Discussions and Round-Table Workshops from key opinion leaders in the field form the basis of this conference.
Monday, December 13, 2021, 1:00 PM PT/4:00 PM ET – Wednesday, Dec 15, 2021, 5:30 PM PT/8:30 PM, ET
Biological Dynamics presents a poster based on the recent study:
Isolation of extracellular vesicles from ovarian, bladder, and pancreatic cancer patient plasma using novel microelectrode array technology compared to ultracentrifugation
Biological Dynamics is proud to sponsor the 6th annual Teal Steps Walk. The event supports community education and awareness outreach programs for ovarian cancer, the most lethal gynecologic cancer. Currently, there is no screening test for the early detection of ovarian cancer, and the overall five-year survival rate is only 45%. However, when detected early, the survival rate is over 90%.
Our participation in the event is closely aligned with our mission to improve global health and save lives by detecting cancer in blood at the earliest stages. We continue to see promising results from our experiments focused on stage I/II ovarian, pancreatic, and bladder cancers, which will advance the development of our multi-cancer screening test for early detection.
Biological Dynamics is a private molecular diagnostics company located in San Diego. Our proprietary technology offers a novel, fast, and cost-effective lab-on-chip ACE platform that isolates nanoparticles from high conductance physiological solutions.
Our product, the TR(ACE)™ assay, will utilize the platform for monitoring treatment response in oncology. TR(ACE)™ has not been cleared or approved by the U.S. FDA or any foreign regulatory agency.
